Vascular Biogenics (VBLT) Set to Announce Earnings on Tuesday

Vascular Biogenics (NASDAQ:VBLTGet Rating) is scheduled to announce its earnings results before the market opens on Tuesday, May 17th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

Vascular Biogenics (NASDAQ:VBLTGet Rating) last posted its earnings results on Wednesday, March 23rd. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.04). Vascular Biogenics had a negative net margin of 3,895.83% and a negative return on equity of 63.08%. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.20 million. During the same quarter last year, the business posted ($0.15) earnings per share. On average, analysts expect Vascular Biogenics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Vascular Biogenics stock traded down $0.01 during mid-day trading on Wednesday, hitting $1.35. 297,443 shares of the stock were exchanged, compared to its average volume of 189,066. Vascular Biogenics has a twelve month low of $1.10 and a twelve month high of $3.04. The stock has a market capitalization of $93.59 million, a price-to-earnings ratio of -3.00 and a beta of 1.09. The company has a 50-day simple moving average of $1.53 and a 200 day simple moving average of $1.75.

Several research firms recently issued reports on VBLT. StockNews.com began coverage on shares of Vascular Biogenics in a research report on Saturday. They issued a “hold” rating on the stock. Zacks Investment Research cut shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 29th. Finally, Chardan Capital began coverage on shares of Vascular Biogenics in a research report on Thursday, April 28th. They issued a “buy” rating and a $5.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Vascular Biogenics presently has an average rating of “Buy” and a consensus price target of $5.05.

A number of hedge funds have recently made changes to their positions in the business. Northern Trust Corp acquired a new position in Vascular Biogenics during the fourth quarter valued at approximately $89,000. Geode Capital Management LLC raised its stake in shares of Vascular Biogenics by 62.1% during the third quarter. Geode Capital Management LLC now owns 40,323 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 15,450 shares during the period. Envestnet Asset Management Inc. purchased a new stake in shares of Vascular Biogenics during the first quarter valued at approximately $64,000. Millennium Management LLC purchased a new stake in shares of Vascular Biogenics during the second quarter valued at approximately $89,000. Finally, Advisor Group Holdings Inc. raised its stake in shares of Vascular Biogenics by 49.2% during the first quarter. Advisor Group Holdings Inc. now owns 36,797 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 12,133 shares during the period. 26.15% of the stock is currently owned by hedge funds and other institutional investors.

About Vascular Biogenics (Get Rating)

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications.

Featured Articles

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.